Are Ramsay Health Care Limited shares cheap?

Arguably one of the biggest disappointments on the market this year has been the Ramsay Health Care Limited (ASX: RHC) share price.

Despite the market climbing almost 7% higher, the Ramsay share price has gone sideways and remains flat year-to-date.

Are Ramsay’s shares cheap?

While they certainly aren’t as cheap as they were around six weeks ago when they traded in or around the $61 mark, I still think they are great value today.

Especially for investors willing to make a buy and hold investment. Thanks to ageing and growing populations, increased chronic disease burden, and improvements in treatments and diagnostic methods, demand for healthcare services is expected to grow at a strong rate for the next couple of decades.

I believe this puts Ramsay and its global private hospital network in a great position to deliver above-average earnings growth for the foreseeable future.

In my opinion, this strong growth potential and its defensive business more than justify its shares changing hands at approximately 28x trailing earnings. Especially when healthcare sector peer Cochlear Limited (ASX: COH) has a similar growth profile but trades at 46x trailing earnings.

Foolish takeaway

Ultimately, although Ramsay’s shares are not conventionally cheap, I think at 28x earnings they have the potential to provide market-beating returns over the next decade.

For this reason I would put the private hospital operator up there as one of the best buy and hold investment options and suggest investors choose it ahead of rivals Healthscope Ltd (ASX: HSO) and Primary Health Care Limited (ASX: PRY).

As well as Ramsay, I think these growth shares are great buy and hold investment options.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.